Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on MRNS. Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. HC Wainwright reissued a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Trading Down 0.2 %

MRNS opened at $0.55 on Friday. The company’s 50 day moving average is $0.52 and its 200-day moving average is $0.83. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50. The company has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MRNS. Assenagon Asset Management S.A. lifted its position in shares of Marinus Pharmaceuticals by 70.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock worth $782,000 after purchasing an additional 183,396 shares during the period. abrdn plc lifted its position in shares of Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after purchasing an additional 1,578,329 shares during the period. GSA Capital Partners LLP lifted its position in shares of Marinus Pharmaceuticals by 409.4% in the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 817,050 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after purchasing an additional 1,253,901 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Marinus Pharmaceuticals by 39.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.